scispace - formally typeset
T

Tapan K. Saikia

Researcher at Tata Memorial Hospital

Publications -  81
Citations -  1182

Tapan K. Saikia is an academic researcher from Tata Memorial Hospital. The author has contributed to research in topics: Leukemia & Myeloid leukemia. The author has an hindex of 19, co-authored 79 publications receiving 1128 citations.

Papers
More filters
Journal ArticleDOI

Consolidation Radiation After Complete Remission in Hodgkin's Disease Following Six Cycles of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Chemotherapy: Is There a Need?

TL;DR: It is suggested that the addition of consolidation radiation helps improve the EFS and OS in patients achieving a complete remission after six cycles of ABVD chemotherapy, particularly in the younger age group and in patients with B symptoms and bulky and advanced disease.
Journal ArticleDOI

Epstein-barr virus association in classical hodgkin's disease provides survival advantage to patients and correlates with higher expression of proliferation markers in reed-sternberg cells

TL;DR: This study suggests that EBV is likely to confer a higher PCNA expression and also contribute towards maintaining the RS cells of cHD in cell cycle, which would make RS cells in EBV associated cHD would be more responsive to chemotherapy and radiotherapy associated DNA damage.
Journal ArticleDOI

Gonadal Function Following ABVD Therapy for Hodgkin's Disease

TL;DR: ABVD is associated with relatively better preservation of gonadal function and three patients treated with ABVD fathered children post-therapy.
Journal ArticleDOI

Pulmonary microsporidial infection in a patient with CML undergoing allogeneic marrow transplant.

TL;DR: A case of microsporidial infection in a female patient with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation is reported, suggesting that transplant patients are another group of patients who are susceptible to this group of opportunistic pathogens.
Journal ArticleDOI

Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia.

TL;DR: Reduced-intensity conditioning that harnesses the potential of a graft-versus-tumor (GVT) effect has been proposed as an alternative to conventional myeloablative allogeneic stem cell transplantation and this can be achieved with minimal immunosuppression in 17 patients who received human leukocyte antigen-matched sibling allografts.